Clinical TrialsThe BEACON, SPOTLIGHT, and OLE study updates create opportunities to demonstrate the competitive profile of briquilimab, acting as catalysts for the stock.
Market PotentialBEACON now includes omalizumab-naive patients, potentially growing the addressable population for JSPR.
Safety ProfileTakeaways from AAAAI data include sustained UAS7 changes and no new safety events, suggesting a continuation of a favorable safety profile.